Who might be predisposed to the development of serious side effects when treated with TNF-alpha antagonist? [3]

Clinical and Experimental Rheumatology

Volumn 24, Issue 2, 2006, Pages 211-

  Kotyla, Przemyslaw J ^a   Kucharz, E J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33744794882     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. BOYER JF, JAMARD B, EL MAHOU S et al.: New-onset acute heart failure and ventricular tachycardia after therapy with tumor necrosis factor antagonist. Clin Exp Rheumatol 2005; 23: 274-5.
2. KOTYLA PJ, KUCHARZ EJ, KOTUISKA A, RAKOCZY J: Treatment with TNF alpha antagonist infliximab does not affect cardiac function in patients with rheumatoid arthritis and preserved left ventricular function; an echocardiographic study. Ann Rheum Dis 2003; 62 (Suppl. 1): 166.
3. LEVINE B, KALMAN J, MAYER L, FILLIT HM. PACKER M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
4. WEI CM, LERMAN A, RODEHEFFER RJ et al: Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-6.
5. BERGER R, HUELSMAN M, STRECKER K et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-7.